LDFWART With Docetaxel in Patients With Platinum-Resistant Recurrent Ovarian Carcinoma

Exclusion Criteria

• •1\. Patients who have received prior radiotherapy to the chest, whole abdomen, or lower extremities above the knees.
• •2\. Patients who have received prior radiation therapy to the head, neck, or lower extremities below the knees if greater than 3 years prior to study entry.
• •3\. Evidence of extra-abdominal extension of disease (such as groin nodes, lung, supraclavicular nodes, and pleural fluid).
• •4\. Patients may not be receiving any other investigational agents within 4 weeks preceding the start of study treatment) or chemotherapy for at least 3 weeks preceding the start of study treatment.
• •5\. Patients who have been diagnosed with another prior malignant tumor within 3 years of study entry, excluding non-melanoma skin cancer and carcinoma in situ of the cervix.
• •6\. Patients with prior history of a severe hypersensitivity reaction to paclitaxel (polysorbate 80-Cremophor).
• •7\. Patients with current history of uncontrolled hypertension, angina pectoris, heart failure, cardiac dysrhythmias, pericardial disease, cardiomyopathy, or active infection.
• •8\. Presence of any medical condition that in the opinion of the investigator deems the patient unable to participate.
• •9\. Females of child-bearing potential. It is expected that ovarian cancer patients would have had a hysterectomy and/or oophorectomy as part of the original standard of care.
• •10\. Patients that are \< 18 yrs. of age or \> 80 yrs. of age.